REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial.
Antidepressants
Deprescribing
Depression
Digital intervention
Discontinuation
Primary care
Withdrawal
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
24 May 2020
24 May 2020
Historique:
received:
24
03
2020
accepted:
23
04
2020
entrez:
26
5
2020
pubmed:
26
5
2020
medline:
30
1
2021
Statut:
epublish
Résumé
Around one in ten adults take antidepressants for depression in England, and their long-term use is increasing. Some need them to prevent relapse, but 30-50% could possibly stop them without relapsing and avoid adverse effects and complications of long-term use. However, stopping is not always easy due to withdrawal symptoms and a fear of relapse of depression. When general practitioners review patients on long-term antidepressants and recommend to those who are suitable to stop the medication, only 6-8% are able to stop. The Reviewing long-term antidepressant use by careful monitoring in everyday practice (REDUCE) research programme aims to identify safe and cost-effective ways of helping patients taking long-term antidepressants taper off treatment when appropriate. Design: REDUCE is a two-arm, 1:1 parallel group randomised controlled trial, with randomisation clustered by participating family practices. England and north Wales. patients taking antidepressants for longer than 1 year for a first episode of depression or longer than 2 years for repeated episodes of depression who are no longer depressed and want to try to taper off their antidepressant use. provision of 'ADvisor' internet programmes to general practitioners or nurse practitioners and to patients designed to support antidepressant withdrawal, plus three patient telephone calls from a psychological wellbeing practitioner. The control arm receives usual care. Blinding of patients, practitioners and researchers is not possible in an open pragmatic trial, but statistical and health economic data analysts will remain blind to allocation. the primary outcome is self-reported nine-item Patient Health Questionnaire at 6 months for depressive symptoms. depressive symptoms at other follow-up time points, anxiety, discontinuation of antidepressants, social functioning, wellbeing, enablement, quality of life, satisfaction, and use of health services for costs. 402 patients (201 intervention and 201 controls) from 134 general practices recruited over 15-18 months, and followed-up at 3, 6, 9 and 12 months. A qualitative process evaluation will be conducted through interviews with 15-20 patients and 15-20 practitioners in each arm to explore why the interventions were effective or not, depending on the results. Helping patients reduce and stop antidepressants is often challenging for practitioners and time-consuming for very busy primary care practices. If REDUCE provides evidence showing that access to internet and telephone support enables more patients to stop treatment without increasing depression we will try to implement the intervention throughout the National Health Service, publishing practical guidance for professionals and advice for patients to follow, publicised through patient support groups. ISRCTN:12417565. Registered on 7 October 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Around one in ten adults take antidepressants for depression in England, and their long-term use is increasing. Some need them to prevent relapse, but 30-50% could possibly stop them without relapsing and avoid adverse effects and complications of long-term use. However, stopping is not always easy due to withdrawal symptoms and a fear of relapse of depression. When general practitioners review patients on long-term antidepressants and recommend to those who are suitable to stop the medication, only 6-8% are able to stop. The Reviewing long-term antidepressant use by careful monitoring in everyday practice (REDUCE) research programme aims to identify safe and cost-effective ways of helping patients taking long-term antidepressants taper off treatment when appropriate.
METHODS
METHODS
Design: REDUCE is a two-arm, 1:1 parallel group randomised controlled trial, with randomisation clustered by participating family practices.
SETTING
METHODS
England and north Wales.
POPULATION
METHODS
patients taking antidepressants for longer than 1 year for a first episode of depression or longer than 2 years for repeated episodes of depression who are no longer depressed and want to try to taper off their antidepressant use.
INTERVENTION
METHODS
provision of 'ADvisor' internet programmes to general practitioners or nurse practitioners and to patients designed to support antidepressant withdrawal, plus three patient telephone calls from a psychological wellbeing practitioner. The control arm receives usual care. Blinding of patients, practitioners and researchers is not possible in an open pragmatic trial, but statistical and health economic data analysts will remain blind to allocation.
OUTCOME MEASURES
METHODS
the primary outcome is self-reported nine-item Patient Health Questionnaire at 6 months for depressive symptoms.
SECONDARY OUTCOMES
RESULTS
depressive symptoms at other follow-up time points, anxiety, discontinuation of antidepressants, social functioning, wellbeing, enablement, quality of life, satisfaction, and use of health services for costs.
SAMPLE SIZE
METHODS
402 patients (201 intervention and 201 controls) from 134 general practices recruited over 15-18 months, and followed-up at 3, 6, 9 and 12 months. A qualitative process evaluation will be conducted through interviews with 15-20 patients and 15-20 practitioners in each arm to explore why the interventions were effective or not, depending on the results.
DISCUSSION
CONCLUSIONS
Helping patients reduce and stop antidepressants is often challenging for practitioners and time-consuming for very busy primary care practices. If REDUCE provides evidence showing that access to internet and telephone support enables more patients to stop treatment without increasing depression we will try to implement the intervention throughout the National Health Service, publishing practical guidance for professionals and advice for patients to follow, publicised through patient support groups.
TRIAL REGISTRATION
BACKGROUND
ISRCTN:12417565. Registered on 7 October 2019.
Identifiants
pubmed: 32448374
doi: 10.1186/s13063-020-04338-7
pii: 10.1186/s13063-020-04338-7
pmc: PMC7245840
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
419Subventions
Organisme : Department of Health
ID : RP-PG-1214-20004
Pays : United Kingdom
Organisme : Programme Grants for Applied Research
ID : RP-PG-1214-20004
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Implement Sci. 2009 May 21;4:29
pubmed: 19460163
BMJ Open. 2020 Mar 8;10(3):e032312
pubmed: 32152159
Int J Epidemiol. 2006 Oct;35(5):1292-300
pubmed: 16943232
Fam Pract. 2014 Oct;31(5):578-84
pubmed: 25121977
BMJ. 2011 Aug 02;343:d4551
pubmed: 21810886
Ment Health Fam Med. 2008 Jun;5(2):105-9
pubmed: 22477855
Health Qual Life Outcomes. 2012 Dec 27;10:156
pubmed: 23270465
BMJ. 2008 Aug 19;337:a884
pubmed: 18713809
BMJ. 2009 Oct 15;339:b3999
pubmed: 19833707
Biol Psychiatry. 1998 Jul 15;44(2):77-87
pubmed: 9646889
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Fam Pract. 2002 Jun;19(3):257-63
pubmed: 11978716
Br J Gen Pract. 2012 Nov;62(604):e773-9
pubmed: 23211181
Fam Pract. 2014 Aug;31(4):419-26
pubmed: 24850795
J Affect Disord. 2017 Oct 15;221:31-35
pubmed: 28628765
Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):22-27
pubmed: 15014625
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Br J Gen Pract. 2007 Aug;57(541):650-2
pubmed: 17688760
J Sex Marital Ther. 2006 Jan-Feb;32(1):43-52
pubmed: 16234225
Br J Psychiatry. 2012 May;200(5):393-8
pubmed: 22442100
Psychopharmacol Bull. 1997;33(4):731-45
pubmed: 9493486
Med Care. 2004 Sep;42(9):851-9
pubmed: 15319610
Health Technol Assess. 2009 Apr;13(22):iii-iv, ix-xi, 1-159
pubmed: 19401066
Fam Pract. 1998 Apr;15(2):165-71
pubmed: 9613486
J Affect Disord. 2015 Jul 15;180:68-78
pubmed: 25881283
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Patient Educ Couns. 2019 Jul;102(7):1389-1396
pubmed: 30905493
JAMA. 2006 Mar 8;295(10):1152-60
pubmed: 16522836
Psychother Psychosom. 2015 Feb 21;84(2):72-81
pubmed: 25721705
Br J Psychiatry. 2009 Sep;195(3):202-10
pubmed: 19721108
Qual Prim Care. 2011;19(2):109-13
pubmed: 21575333